NO20052479L - Tramadolformuleringer med forsinket frigjoring og 24 timers effektivitet - Google Patents

Tramadolformuleringer med forsinket frigjoring og 24 timers effektivitet

Info

Publication number
NO20052479L
NO20052479L NO20052479A NO20052479A NO20052479L NO 20052479 L NO20052479 L NO 20052479L NO 20052479 A NO20052479 A NO 20052479A NO 20052479 A NO20052479 A NO 20052479A NO 20052479 L NO20052479 L NO 20052479L
Authority
NO
Norway
Prior art keywords
delayed release
release tramadol
tramadol formulations
hour efficacy
efficacy
Prior art date
Application number
NO20052479A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052479D0 (no
Inventor
Vincent Lenaerts
Patricia Laure Ouadji-Njiki
Jonathan Bacon
Rachid Quzerourou
Sonia Gervais
Miloud Rahmouni
Damon Smith
Original Assignee
Labopharm Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32179487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052479(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Labopharm Europe Ltd filed Critical Labopharm Europe Ltd
Publication of NO20052479L publication Critical patent/NO20052479L/no
Publication of NO20052479D0 publication Critical patent/NO20052479D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20052479A 2002-10-25 2005-05-23 Tramadolformuleringer med forsinket frigjoring og 24 timers effektivitet NO20052479D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28102602A 2002-10-25 2002-10-25
US51037803P 2003-10-10 2003-10-10
PCT/CA2003/001638 WO2004037222A2 (fr) 2002-10-25 2003-10-27 Preparations de tramadol a liberation soutenue dotees d'une efficacite de 24 heures

Publications (2)

Publication Number Publication Date
NO20052479L true NO20052479L (no) 2005-05-23
NO20052479D0 NO20052479D0 (no) 2005-05-23

Family

ID=32179487

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052479A NO20052479D0 (no) 2002-10-25 2005-05-23 Tramadolformuleringer med forsinket frigjoring og 24 timers effektivitet

Country Status (11)

Country Link
JP (1) JP2006507277A (fr)
KR (1) KR20050083816A (fr)
AR (1) AR045972A1 (fr)
AU (1) AU2003275855B2 (fr)
CA (1) CA2503155A1 (fr)
IL (1) IL168114A (fr)
NO (1) NO20052479D0 (fr)
PT (1) PT1594460E (fr)
RU (1) RU2328275C2 (fr)
UA (1) UA84277C2 (fr)
WO (1) WO2004037222A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1905435A3 (fr) * 2003-03-11 2008-05-14 Euro-Celtique S.A. Régime de dosage de titrage pour tramadol à libération contrôlée
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
BRPI0511137A (pt) * 2004-05-14 2007-11-27 Janssen Pharmaceutica Nv compostos opióides de carboxamido
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PL1931346T3 (pl) * 2005-09-09 2013-01-31 Angelini Labopharm Llc Kompozycja trazodonu do podawania raz na dobę
HUE029173T2 (hu) * 2006-04-26 2017-02-28 Alphapharm Pty Ltd Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
TWI524904B (zh) 2008-05-09 2016-03-11 歌林達股份有限公司 製備醫藥用固體劑型,尤指錠劑之方法,及製備固體劑型,尤指錠劑之前驅物之方法
AU2009253739B2 (en) 2008-05-27 2014-02-06 Otolanum Ag Methods of treating mammals with eustachian tube dysfunctions
CA2741751C (fr) * 2008-10-27 2017-05-09 Alza Corporation Forme posologique orale d'acetaminophene/tramadol a liberation prolongee
CA2765971C (fr) 2009-07-22 2017-08-22 Gruenenthal Gmbh Forme galenique extrudee a chaud a liberation controlee
JP2012533586A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化安定化された不正使用防止剤形
ES2606227T3 (es) 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
WO2013156453A1 (fr) 2012-04-18 2013-10-24 Grünenthal GmbH Forme pharmaceutique inviolable et résistante à la libération massive
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
CA2913209A1 (fr) 2013-05-29 2014-12-04 Grunenthal Gmbh Forme dosifiee inviolable a profil de liberation bimodale
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
EP3073994A1 (fr) 2013-11-26 2016-10-05 Grünenthal GmbH Préparation de composition pharmaceutique en poudre par cryo-broyage
EP3142646A1 (fr) 2014-05-12 2017-03-22 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
EP3346991A1 (fr) 2015-09-10 2018-07-18 Grünenthal GmbH Protection contre un surdosage par voie orale à l'aide de formulations à libération immédiate dissuasives d'abus
EP3452024A1 (fr) * 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Compositions pharmaceutiques à perméation améliorée

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
WO1999001111A1 (fr) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Formulations de tramadol stabilisees a liberation prolongee
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
DE10108122A1 (de) * 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol

Also Published As

Publication number Publication date
AU2003275855B2 (en) 2009-04-23
RU2328275C2 (ru) 2008-07-10
AR045972A1 (es) 2005-11-23
UA84277C2 (ru) 2008-10-10
IL168114A (en) 2011-05-31
WO2004037222A2 (fr) 2004-05-06
KR20050083816A (ko) 2005-08-26
JP2006507277A (ja) 2006-03-02
PT1594460E (pt) 2008-06-27
CA2503155A1 (fr) 2004-05-06
WO2004037222A3 (fr) 2005-09-22
RU2005115855A (ru) 2006-01-20
AU2003275855A1 (en) 2004-05-13
NO20052479D0 (no) 2005-05-23

Similar Documents

Publication Publication Date Title
NO20052479L (no) Tramadolformuleringer med forsinket frigjoring og 24 timers effektivitet
NO20050379L (no) Anvendelse av venlafaxinhydroklorid for fremstilling av en innkapslet forlenget frigjoringsblanding
HK1101355A1 (en) Sustained-release tramadol formulations with 24-hour efficacy 24
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
MXPA04009977A (es) Formulaciones de tramadol de liberacion sostenida con eficacia clinica durante 24 horas.
NO20051389L (no) Stabilisert farmasoytisk blanding inneholdende basiske hjelpemidler
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
NO20062513L (no) Sammensetninger og doseringsformer for forsterket absorpsjon av metformin
NO20050771L (no) Bicifadinformulering
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
DK1572153T3 (da) Fremstilling af sterile vandige suspensioner, som omfatter mikroniserede krystallinske virksomme stoffer til inhalering
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
TW200626141A (en) Crystalline form of a drug
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application